MV Hospital and Research Center Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2010
NCT01257906
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

M.V. Hospital and Research Centre, 314/30, Mirza Mandi, Chowk, Lucknow- 226003, India | MV Hospital for Diabetes (P) Ltd

Active Ingredients

Drugs in Phase 3 Trials (3)

ceftriaxone (rocephin) (1 trial)

meropenem (merrem) (1 trial)

sulbactam (unasyn) (1 trial)

Drugs in Phase 2 Trials (1)

grc 17356 (1 trial)

Drugs in Other Trials (2)

clindamycin (cleocin) (1 trial)

tretinoin (Retin-A) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 3)

Diabetic Neuropathies (Phase 2)

Infections (Phase 3)

Pain (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Pyelonephritis (Phase 3)

Urinary Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 6